SwissNeuroRehab High-Dose, High-Intensity Neurorehabilitation Program for Adults With Stroke Across Care Settings

What this Trial Is About

Researchers are evaluating a high-dose, high-intensity HDHI neurorehabilitation program for adults who have experienced a stroke. This study is part of the SwissNeuroRehab initiative, which aims to develop and test innovative, technology-supported rehabilitation models across Switzerland. The focus is on understanding the feasibility and early effects of this program when delivered in real-world clinical settings during both subacute and chronic stages of stroke recovery. Participants will engage in a tailored HDHI therapy pathway using CE-marked digital neurorehabilitation devices, such as MindMotion GO and Izar. The program spans inpatient rehabilitation lasting 4 to 6 weeks and outpatient home-based care for 8 to 12 weeks. Participants are expected to complete about one hour of active, device-assisted training five days a week, in addition to their standard rehabilitation care. Clinical teams trained in the HDHI protocol will supervise and support participants throughout the process. During the study, participants will undergo standardized clinical assessments and report outcomes at the start, end, and follow-up visits up to 12 to 15 months after enrollment. Researchers will monitor adherence to the training schedule, participant satisfaction, and various functional measures such as motor ability, balance, walking tests, and independence in daily activities. Socioeconomic impacts will also be assessed through surveys and cost data. The overall study duration includes up to 18 weeks of intervention with extended follow-up for outcomes and feasibility evaluation.

SwissNeuroRehab - HDHI